An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms PIONEER-OLE
- Sponsors MyoKardia
- 30 Oct 2018 According to a MyoKardia media release, the company plans to present additional interim clinical data from this study in the first quarter of 2019, including gradient and ejection fraction data from longer term exposures, NT-proBNP and NYHA functional classification changes.
- 30 Oct 2018 Interim twelve-week data (n=7) from this study presented in an MyoKardia media release.
- 10 May 2018 According to a MyoKardia media release, first interim data are expected in the first quarter of 2019.